Over the Counter Natural Cures (28 page)

9. “Preventing skin cancer.” Centers for Disease Control. October 17, 2003. www. cdc.gov/mmwr/preview/mmwrhtml/rr5215a1.htm.

10. Nasa Advanced Supercomputing Division. www.nas.nasa.gov/About/Education/ Ozone/controversy.html.

11. B. Jackson “Cosmetic considerations and nonlaser cosmetic procedures in ethnic skin.”
Dermatologic Clinics
. 2003; 21(4): 703–712.

12. Lester Packer, Eric Witt, and Hans Jurgen Tritschler. “Alpha lipoic acid as a biological antioxidant.”
Free Radical Biology and Medicine
. 1995; 19(2): 227–250.

13. Amy Ellis Nutt. “The end of aging.”
Readers Digest
. November 2003, 70; Anna Bilska and Lidia Wlodek. “Lipoic Acid—The drug of the future?”
Pharmacological Reports
. 2005; 57: 570–577; The Cleveland Clinic. my.clevelandclinic.org/healthy_living/skin_care/hic_understanding_the_ingredients_in_skin_care_products.aspx.

14. Lester Packer, Eric Witt, and Hans Jurgen Tritschler. “Alpha lipoic acid as a biological antioxidant.”
Free Radical Biology and Medicine
. 1995; 19(2): 227–250.

15. American Heart Association. americanheart.mediaroom.com/index.php?s= 43&item=545.

16. Sirakarnt Dhitavat, et al. “Acetyl-l-carnitine protects against amyloid-beta neurotoxicity: roles of oxidative buffering and ATP levels.”
Neurochemical
Research.
2002; 27(6).

17. Helen White. “Acetyl-l-carnitine as a precursor of acetylcholine.”
Neurochemical
Research.
1990; 15(6).

18. Vincent W. Delagarza. “Pharmacological treatment of Alzheimer's disease.”
American Family Physician
. October 1, 2003.

 

Chapter 2

19. Michelle Chen. “Discovery of toxins in newborn blood causes alarm, spurs activism.”
New Standard.
July 21, 2005. www.ewg.org/node/17733.

20. Environmental Working Group. “A national assessment of tap water quality.” (More than 140 contaminants with no enforceable safety limits found in the nation's drinking water.) December 20, 2005. www.ewg.org/tapwater/findings.php.

21. Centers for Disease Control. www.cdc.gov/omhd/populations/HL/HL.htm#Ten.

22. Environmental Working Group. “Triclosan in your home.” 2009. www.ewg. org/node/26752.

23. Cane Rogers. Regulatory Status of Triclosan and Triclocarban in Nonprescription Products. Pacific Southwest Organic Residuals Symposium University of California, Davis. October 1, 2008.

24. Antonia M. Calafat, Xiaoyun Ye, Lee-Yang Wong, John A. Reidy, and Larry L. Needham. “Urinary concentrations of triclosan in the U.S. population: 2003–2004.”
Environmental Health Perspectives
. April 23, 2008.

25.
Fluoride in Drinking Water: A Scientific Review of EPA's Standards
.

26. Sara Shahriari. “Columbia searching for answers to high trihalomethanes in water.”
Columbia Missourian
. July 15, 2008. www.columbiamissourian.com/ stories/2008/07/15/tests-find-higher-levels-carcinogen-columbias-drink/.

27. Sean Gray, et al. “Farm runoff, chlorination by-products, and human health.” Environmental Working Group. 2002.

28. Tom Avril. “Philadelphia's water puts pregnant women at risk, study says.”
Philadelphia Inquirer.
January 9, 2002.

29. Juliet Eilperin. “EPA unlikely to limit perchlorate in tap water.”
Washington
Post
. September 22, 2008, A09.

30. Centers for Disease Control. www.cdc.gov/mmwr/preview/mmwrhtml/ mm5008a2.htm.

31. Linda Marsa. “Filtering out the mystery surrounding liver damage.”
Los Angeles
Times
. September 5, 2005.

32. Anne Larson, et al. “Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study.”
Hepatology.
2005; 2(6).

33. Mayo Clinic. “Milk thistle (
Silybum mariamun
).” 2009. www.mayoclinic.com/ health/silymarin/NS_patient-milkthistle.

34. A. Pares, et al. “Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized, and multicenter trial.”
Journal of Hepatology.
1998; 28(4): 615–621.

35. Jhy-Wen Wu, Lie-Chwen Lin and Tung-Hu Tsai. “Drug–drug interactions of silymarin on the perspective of pharmacokinetics.”
Journal of
Ethnopharmacology
. 2009; 121(2): 185–193.

36. G. Buzzelli, S. Moscarella, and A. Giusti, et al. “A pilot study on the liver protective effect of silybinphosphatidylcholine complex (IdB1016) in chronic active hepatitis.”
International Journal of Clinical Pharmacology, Therapy, and
Toxicology
. 1993; 31(9): 456–460; Ladas E.J., Kelley K.M. “Milk thistle: is there
a role for its use as an adjunct therapy in patients with cancer?”
Journal of
Alternative Complementary Medicine.
2003; 9(3): 411–416.
V. Lawrence, B. Jacobs, C. Dennehy, et al. “Report on milk thistle: effects on liver disease and cirrhosis and clinical adverse effects.” Evidence Report/Technology Assessment No. 21 (Contract 290-97-0012 to the San Antonio Evidence-based Practice Center, based at the University of Texas Health Science Center at San Antonio, and The Veterans Evidence-based Research, Dissemination, and Implementation Center, a Veterans Affairs Services Research and Development Center of Excellence). AHRQ Publication No. 01-E025. Rockville, Maryland: Agency for Healthcare Research and Quality. October 2000.
M.I. Lucena, R.J. Andrade, and J.P. de la Cruz, et al. “Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis.” (Results of a randomized, double-blind, placebo-controlled clinical study.)
International
Journal of Clinical Pharmacology and Therapeutics
. 2002; 40(1): 2–8.
A. Madisch, H. Melderis, and G. Mayr, et al
.
“A plant extract and its modified preparation in functional dyspepsia. Results of a double-blind placebo controlled comparative study.”
Z Gastroenterol
. 2001; 39(7): 511–517.
A. Melhelm, M. Stern, and O. Shibolet, et al
.
“Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial.”
J. Clin.
Gastroenterol
. 2005; 39(8): 737–42.
A. Pares, R. Planas, and M. Torres, et al
.
“Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized, and multicenter trial.”
Journal of Hepatology
. 1998; 28(4): 615–621.
A. Rambaldi, B.P. Jacobs, and G. Iaquinto, et al. “Milk thistle for alcoholic and/ or hepatitis B or C liver diseases—a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials.”
American Journal of
Gastroenterology
. 2005; 100(11): 2583–91.
A. Rambaldi, B.P. Jacobs, and C. Gluud, et al. “Milk thistle for alcoholic and/ or hepatitis B or C virus liver diseases.” Cochrane Database Syst Rev. October 17, 2007; (4):CD003620. Update of Cochrane Database Syst. Rev. 2005; (2): CD003620.
F.H. Schroder, M.J. Roobol, and E.R. Boeve, et al
.
“Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.”
European Urology
. 2005; 48(6): 922–30; discussion 930–1.
A.K. Tyagi, R.P. Singh, and C. Agarwal, et al
.
“Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis.”
Clinical Cancer Research
. 2002; 8(11): 3512–19.

 

Chapter 3

37. E.H. Reynolds. “Folic acid, aging, depression, and dementia.”
British Medical
Journal
. 2002; 324(7352): 1512–1515; Walter Willett and Meir Stampfer. “What
vitamin should I be taking doctor?”
New England and Journal of Medicine
. 2001; 345(25).

38. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Conflicts of Interest: Financial Disclosure. www.nhlbi.nih.gov/guidelines/hypertension/ disclose.htm.

39. Kash Rizvi, John P. Hampson, and John N. Harvey. “Do lipid-lowering drugs cause erectile dysfunction? A systematic review.”
Family Practice
. 2002; 19(1): 95–98.

40. Ed Edelson. “FDA investigates possible vytorin-cancer link.”
U.S. News &
World Report
. August 22, 2008.

41. Alex Berenson. “For widely used drug, question of usefulness is still lingering.”
New York Times
. September 2, 2008.

42. Avery Johnson. “A risk in cholesterol drugs is detected, but is it real?”
Wall
Street Journal
. July 3, 2007.

43. Barbara Starfield. “Is U.S. health really the best in the world?”
Journal of the
American Medical Association
. 2000; 284(4).

44. Steve Sternberg. “Warning labels urged for cholesterol drugs
.
”
USA Today
. August 20, 2001.

45. P.S. Sever, B. Dahlof, N.R. Poulter, and H. Wedel. The Anglo-Scandinavian Cardiac Outcomes Trial: Morbidity-mortality outcomes in the blood pressure lowering arm of the trial (ASCOT-BPLA). American College of Cardiology Annual Scientific Session 2005, March 6–9, Orlando, Florida. Late Breaking Clinical Trials 2.

46. Therapeutics Initiative. “Evidence-based drug therapy. Do statins have a role in primary prevention?” April–June 2003. The University of British Columbia. www.ti.ubc.ca.

47. Sonia Brescianini, MS, Stefania Maggi, MD, Gino Farchi, MS, Sergio Mariotti, MS, Antonio Di Carlo, MD, Marzia Baldereschi, MD, and Domenico Inzitari for the ILSAGroup. “Low total cholesterol and increased risk of dying: are low levels clinical warning signs in the elderly?” (Results from the Italian Longitudinal Study on Aging.)
Journal of the American Geriatrics Society
. 2003; 51(7): 991.

48. K.M. Anderson, W.P. Castelli, and D. Levy. “Cholesterol and mortality.” (thirty years of follow-up from the Framingham study.)
Journal of the American
Medical Association
. 1987; 257(16): 2176–2180.

49. The total death rates in the low-dose and in the high-dose atorvastatin groups were 5.6 and 5.7 percent, respectively.

50. Pam Belluck. “Cholesterol-fighting drugs show wider benefit.”
New York
Times
. November 9, 2008.

51. M.A. Hlatky. Letter to the Editor.
New England Journal of Medicine
. 2008; 359: 2280–2282.

52. Joe Collier and Ike Iheanacho. “The pharmaceutical industry as an informant.”
Lancet
. 2002; 360: 1405–1409.

53. John Abramson and Barbara Starfield. “The effect of conflict of interest on biomedical research and clinical practice guidelines: can we trust the evidence in evidence-based medicine?”
Journal of the American Board of Family Medicine.
2005; 18(5).

54. K.L. Phua and F.I. Achike. “Vioxx and other pharmaceutical product withdrawals: ethical issues in ensuring the integrity of drug and medical device research, development, and commercialization.”
Clinical Ethics.
2007; 2: 155–162.

55. Naveed Akhtar. “Is homocysteine a risk factor for atherothrombotic cardiovascular disease?”
Journal of the American College of Cardiology
. 2007; 49(12): 1370–1371.

56. William Cromie. “B vitamins cut heart disease risk for women.”
The Harvard
University Gazette.
February 5, 1998.

57. www.bmj.com/cgi/content/full/333/7578/1114

58. Lisa Davis. “Custom-fit vitamins.”
Readers Digest.
November 2001, 88.

59. S. Hirsch, H. Sanchez, C. Albala, M.P. de la Maza, G. Barrera, L. Leiva, and D.
Bunout. “Colon cancer in Chile before and after the start of the flour fortification program with folic acid.”
European Journal of Gastroenterology Hepatology
. 2009 Apr; 21(4): 436–9.

 

Chapter 4

60. Lara Moscrip. “High cost of health in golden years.”
CNN Money
. June 3, 2008. http://money.cnn.com/2008/06/03/pf/retirement/retiree_health/ index. htm?postversion=2008060318.

61. J. Weil, D. Colin-Jones, M. Langman, D. Lawson, R. Logan, M. Murphy, M. Rawlins, M. Vessey, and P. Wainwright. “Prophylactic aspirin and risk of peptic ulcer bleeding.”
British Medical Journal
. 1995; 310(6983) 827–830; Reuters. “Aspirin no heart protection for diabetics: study.” Wire story, October 17, 2008.

62. U.S. Department of Health and Human Services. www.nih.gov/news/pr/ mar2005/nhlbi-07.htm.

63. John Weil, et al. “Prophylactic aspirin and risk of peptic ulcer bleeding.”
British
Medical Journal.
1995; 310: 827–830.

64. Michael Tauchert. “Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association Class III heart failure.”
American Heart Journal.
2002; 143(5): 910–915.

65. Brenda Goodman. “Questions are raised about the safety of a major heart drug.”
New York Times
. March 13, 2006.

66. George Bakris. “Apply antihypertensive therapy for patients with type 2 diabetes.”
Medscape Today
. www.medscape.com/viewarticle/536351_14.

67. www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T0Y-48J0811-G& _user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct= C000050221&_version=1&_urlVersion=0&_userid=10&md5=094c16364c30 ed943b96ca1ac0f0a2bc.
www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1836829.
www.physiciansweekly.com/article.asp?issueid=334&articleid=3125.
www.jstor.org/pss/3702453.

68. Michael Tauchert. “Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association Class III heart failure.”
American Heart Journal.
2002; 143(5): 910–915.

69. Ann Walker, et al. “Promising hypotensive effect of hawthorn extract: a
randomized double-blind pilot study of mild, essential hypertension.”
Phytotherapy Research
. 2002; 16(1): 48–54.